Published in AJR Am J Roentgenol on October 01, 2004
Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics (2011) 2.17
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging (2006) 1.35
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26
Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am (2008) 1.24
Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol (2006) 1.23
MR imaging of the prostate in clinical practice. MAGMA (2008) 1.15
Multiparametric magnetic resonance imaging of prostate cancer. Indian J Radiol Imaging (2012) 1.09
Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol (2009) 1.04
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res (2009) 1.03
Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol (2010) 1.02
Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging (2015) 0.99
New horizons in prostate cancer imaging. Eur J Radiol (2008) 0.99
Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol (2010) 0.98
Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol (2006) 0.95
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery. Asian J Androl (2014) 0.86
Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma. BMC Urol (2015) 0.85
Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl (2014) 0.85
Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. Radiology (2009) 0.85
Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology (2012) 0.84
Fast T2*-weighted MRI of the prostate at 3 Tesla. J Magn Reson Imaging (2011) 0.81
Significance of postbiopsy hemorrhage observed on preoperative magnetic resonance imaging in performing robot-assisted laparoscopic radical prostatectomy. World J Urol (2010) 0.81
Modalities for imaging of prostate cancer. Adv Urol (2010) 0.80
Effects of post biopsy digital rectal compression on improving prostate cancer staging using magnetic resonance imaging in localized prostate cancer. Yonsei Med J (2013) 0.78
Effect of Prostate Biopsy Hemorrhage on MRDW and MRS Imaging. Korean J Urol (2011) 0.78
Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia (2007) 0.77
Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. Prostate Int (2015) 0.77
Value of T1/T2-weighted magnetic resonance imaging registration to reduce the postbiopsy hemorrhage effect for prostate cancer localization. Prostate Int (2015) 0.75
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. J Urol (2005) 0.75
The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score. Asian J Androl (2011) 0.75
Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate. Prostate Cancer Prostatic Dis (2015) 0.75
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
The yeast cell-cycle network is robustly designed. Proc Natl Acad Sci U S A (2004) 6.76
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res (2008) 4.79
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med (2013) 4.23
Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med (2007) 4.13
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet (2008) 3.95
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res (2004) 3.77
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology (2003) 3.36
Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. J Magn Reson (2007) 3.35
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
T2 relaxation time of cartilage at MR imaging: comparison with severity of knee osteoarthritis. Radiology (2004) 3.24
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol (2009) 2.97
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A (2005) 2.59
Diffusion tensor imaging: serial quantitation of white matter tract maturity in premature newborns. Neuroimage (2004) 2.58
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Compressed sensing for resolution enhancement of hyperpolarized 13C flyback 3D-MRSI. J Magn Reson (2008) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology (2002) 2.26
CT and MR imaging of pericardial disease. Radiographics (2003) 2.19
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 2.16
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson (2009) 2.05
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab (2011) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Imaging of retained surgical sponges in the abdomen and pelvis. AJR Am J Roentgenol (2003) 2.02
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol (2002) 2.00
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 1.97
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
3D compressed sensing for highly accelerated hyperpolarized (13)C MRSI with in vivo applications to transgenic mouse models of cancer. Magn Reson Med (2010) 1.92
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) (2010) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
Urology resident publication output and its relationship to future academic achievement. J Urol (2010) 1.85
Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson (2010) 1.84
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am J Roentgenol (2007) 1.83
New two-dimensional metal-organic networks constructed from 1,2,4,5-benzenetetracarboxylate and chelate ligands. Inorg Chem (2003) 1.83
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Distinguishing features of self-limiting adult small-bowel intussusception identified at CT. Radiology (2003) 1.76
Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol (2008) 1.73